

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/767,686
		Filing Date	01/29/2004
		First Named Inventor	Ai-Zhi Piao
		Art Unit	1615
Examiner Name			
Sheet 1	of 2	Attorney Docket Number	T8275.DIV

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
559	1	✓ AS Sawhney and JA Hubbell, <u>Rapidly Degraded Terpolymers of dl-Lactide, Glycolide, and εCaprolactone with Increased Hydrophilicity by Copolymerization with Polyethers</u> , J. Biomed. Mat. Res., 24, 1397-1411 (1990).	
959	2	✓ AS Sawhney, CP Pathak, and JA Hubbell, <u>Bioerodible Hydrogels Based on Photopolymerized Poly(ethylene glycol)-c9-poly(α-hydroxy acid) Diacrylate Macromers</u> , Macromolecules, 26(4), 581-589: 1993.	
559	3	✓ T Matsuda, N Motomura, and T Oka, <u>Angiopeptin as a Potent Inhibitor of Myointimal Hyperplasia: Systemic Injection and Local Administration via Impregnation in a Biodegradable Polymeric Gel</u> , ASAIO Journal, M512-M517(1993).	
559	4	✓ L Martini et al., <u>Micellisation and Gelation of Triblock Copolymer of Ethylene Oxide and ε-Caprolactone, CLE, CL in Aqueous Solution</u> , J. Chem Soc. Faraday Trans., 90(13), 1961-1966: 1994.	
559	5	✓ TP Johnston and SC Miller, <u>Inulin Diposition Following Intramuscular Administration of an Inulin/Poloxamer Gel Matrix</u> , J. Parenteral Science & Technology, 43(6), November-December 1989.	
559	6	✓ TP Johnston et al., <u>Sustained Delivery of Interleukin-2 from a Poloxamer 407 Gel Matrix Following Intraperitoneal Injection in Mice</u> , Pharmaceutical Research 9(3), 1992.	
559	7	✓ K Morikawa et al., <u>Enhancement of Therapeutic Effects of Recombinant Interleukin 2 on a Transplantable Rat Fibrosarcoma by the Use of a Sustained Release Vehicle, Pluronic Gel</u> , Cancer Research, 47 pp. 37-41, January 1, 1987.	
559	8	✓ TP Johnston and SC Miller, <u>Toxicological Evaluation of Poloxamer Vehicles for Intramuscular Use</u> , J. Parenteral Science and Technology, 39(2), March-April 1985.	
559	9	✓ L. Youxin, C Volland, and T Kissel, <u>In-Vitro Degradation and Bovine Serum Albumin Release of the ABA Triblock Copolymers Consisting of poly (L(+)-lactic acid-co-glycolic acid) A-Blocks attached to Central Polyoxethylene B-Blocks</u> , J. Controlled Release, 32: 1994.	
559	10	✓ L. Youxin and T Kissel, <u>Synthesis and Properties of Biodegradable ABA Triblock Copolymers Consisting of poly (L-lactic acid) or poly (L-lactic-co-glycolic acid) A-Blocks attached to Central Poly(oxethylene) B-Blocks</u> , J. Controlled Release, 27: 1993.	

Examiner Signature	<i>[Signature]</i>	Date Considered	3/23/06
--------------------	--------------------	-----------------	---------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/767,686		
		Filing Date	01/29/2004		
		First Named Inventor	Ai-Zhi Piao		
		Art Unit	1615		
		Examiner Name			
Sheet	2		2	Attorney Docket Number	T8275.DIV


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
5/5/04	11	KA FULTS and TP JOHNSTON, <u>Sustained-Release of Urease from a Poloxamer Gel Matrix</u> , J. Parenteral Science & Technology, 44(2), March-April 1990.	
6/1/04	12	Byeongmoon Jeong, et al, " <u>Biodegradable Block Copolymers as Injectable Drug-delivery Systems</u> ", Letters to Nature, Vol. 388, 28 August 1997. ✓	
5/4/04	13	A Chenite, et al, " <u>Novel Injectable Neutral Solutions of Chitosan Form Biodegradable Gels In Situ</u> ", Biomaterials, 21 (2000) 2155-2161. ✓	
4/5/04	14	E. Ruel-Gariepy, et al, " <u>Thermosensitive Chitosan-based Hydrogel Containing Liposomes for the Delivery of Hydrophilic Molecules</u> ", Journal of Controlled Release, 82 (2002) 373-383.	

Examiner Signature		Date Considered	3/23/06
--------------------	---	-----------------	---------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/767,686
Filing Date	01/29/2004
First Named Inventor	Ai-Zhi Piao
Art Unit	1615
Examiner Name	
Attorney Docket Number	T8275.DIV

Sheet 1 of 1

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
gla		4,438,253	3/20/1984	Casey et al.	
		4,526,938	7/2/1985	Churchill et al.	
		4,652,441	3/24/1987	Okada et al.	
		4,745,160	5/17/1988	Churchill et al.	
		4,892,903	1/9/1990	Himes	
		4,938,763	7/3/1990	Dunn et al.	
		5,100,669	3/31/1992	Hyon et al.	
		5,278,202	1/11/1994	Dunn et al.	
		5,324,519	6/28/1994	Dunn et al.	
		5,330,768	7/19/1994	Park et al.	
		5,643,605	7/1/1997	Cleland et al.	
		5,674,192	10/7/1997	Sahatjian et al.	
		5,702,717	12/30/1997	Cha et al.	
		5,814,340	9/29/1998	Labrie et al.	
		5,939,485	8/17/1999	Bromberg et al.	
gla		6,004,573	12/21/1999	Rathi et al.	
		6,117,949	9/12/2000	Rathi et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>2</sup> - Number <sup>3</sup> - Kind Code <sup>4</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
gla		WO 93/24150	12-09-1993	Zeneca Limited		
gla		EP 0258780	03-09-1988	American Cyanamid Company		
gla		EP 0224389	06-03-1987	Raychem Corporation		
gla		EP 0092918	11-02-1983	Imperial Chemical Industries PLC		


Examiner  
SignatureDate  
Considered

3/23/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Approved for use through 07/31/2006. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

(Use as many sheets as necessary)

Application Number	10/767,686
Filing Date	01/29/2004
First Named Inventor	Ai-Zhi Piao
Art Unit	1615
Examiner Name	
Attorney Docket Number	T8275.DIV

Sheet	1	of	1
-------	---	----	---

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>2</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
54		WO 00/66085	11/09/2000	MacroMed		
64		JP 2078629	03/19/1999	TAKI Chemical KK		

Examiner Signature	<i>[Signature]</i>	Date Considered	3/23/06
-----------------------	--------------------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.** If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.